CD155 (PVR)-muIg Fusion Protein (preservative free)
| Code | Size | Price |
|---|
| ANC-555-820-25ug | 25 ug | £473.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Target Species: Human
Shipping:
BI
Storage:
+4°C
Further Information
Alternate Names/Synonyms:
PVR; Polio Virus Receptor; Necl-5
Concentration:
0.5mg/ml
EClass:
32160000
Form (Short):
liquid
Formulation:
50mM Sodium Phosphate pH 7.5, 100mM Potassium Chloride, 150mM NaCl.
Handling Advice:
Avoid freeze/thaw cycles.Keep sterile.
Labels - Conjugates:
Preservative Free
Long Description:
Recombinant protein. Source/Host: CHO cells. Purity: Protein A purified.. 50mM Sodium Phosphate pH 7.5, 100mM Potassium Chloride, 150mM NaCl. Human CD155 (Polio Virus Receptor, PVR, Necl-5) is a 70kd type I Ig superfamily molecule. It is involved in formation of intracellular junctions between epithelial cells. Its ligands include CD226 (DNAM-1), and CD96 (TACTILE). CD155 expression by tumor has been shown to be upregulated by nitric oxide. A soluble version of CD155 has been shown to exist. High CD155 expression has recently been exploited to use engineered poliovirus to treat glioblastoma.
Molecular Weight:
~61kDa
NCBI, Uniprot Number:
P15151
Package Type:
Plastic Vial
Product Description:
Human CD155 (Polio Virus Receptor, PVR, Necl-5) is a 70kd type I Ig superfamily molecule. It is involved in formation of intracellular junctions between epithelial cells. Its ligands include CD226 (DNAM-1), and CD96 (TACTILE). CD155 expression by tumor has been shown to be upregulated by nitric oxide. A soluble version of CD155 has been shown to exist. High CD155 expression has recently been exploited to use engineered poliovirus to treat glioblastoma.
Source / Host:
CHO cells
TAGs:
Fc
Transportation:
Non-hazardous
UNSPSC Category:
Other Proteins
UNSPSC Number:
12352202
Use & Stability:
Stable for at least 6 months after receipt when stored at +4°C.
Related Products
| Product Name | Product Code | Supplier | anti-CD155 (PVR) (human) mAb (ANC2B2) | ANC-255-020 | Ancell | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| anti-CD155 (PVR) (human) mAb (ANC2B2) (Biotin) | ANC-255-030 | Ancell | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| anti-CD155 (PVR) (human) mAb (ANC2B2) (FITC) | ANC-255-040 | Ancell | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| anti-CD155 (PVR) (human) mAb (ANC2B2) (R-PE) | ANC-255-050 | Ancell | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| anti-CD155 (PVR) (human), mAb (ANC6A3) | ANC-350-020 | Ancell | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| anti-CD155 (PVR) (human), mAb (ANC6A3) (Biotin) | ANC-350-030 | Ancell | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| anti-CD155 (PVR) (human), mAb (ANC6A3) (FITC) | ANC-350-040 | Ancell | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CD155 (PVR)-muIg Fusion Protein | ANC-555-020 | Ancell | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CD155 (PVR)-muIg Fusion Protein (Biotin) | ANC-555-030 | Ancell | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||